Reversine, a substituted purine, exerts an inhibitive effect on human renal carcinoma cells via induction of cell apoptosis and polyploidy
Authors Cheng L, Wang H, Guo KC, Wang ZC, Zhang ZY, Shen C, Chen L, Lin J
Received 27 November 2017
Accepted for publication 17 January 2018
Published 26 February 2018 Volume 2018:11 Pages 1025—1035
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Cho
Li Cheng,1,2,* Hao Wang,3,* Kecun Guo,4 Zicheng Wang,1,2 Zhongyuan Zhang,1,2,5 Cheng Shen,1,2,5 Liang Chen,6 Jian Lin1,2,5
1Department of Urology, Peking University First Hospital, Beijing, China; 2Institute of Urology, Peking University, Beijing, China; 3Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; 4Department of Urology, The Second People’s Hospital of Liaocheng, Shandong, China; 5National Urological Cancer Center, Beijing, China; 6Medical Center of Reproductive and Genetics, Peking University First Hospital, Beijing, China
*These authors contributed equally to the paper
Background: Human renal cell carcinoma (RCC) is the most common type of kidney cancer that arises from the renal epithelium. Up to 33.3% of RCC patients treated with local tumor resections will subsequently develop recurrence or metastases. Thus, optimized therapeutic regimes are urgently needed to improve the prognosis of RCC. Reversine was recently reported to exert critical roles in cancer therapy.
Materials and methods: This study evaluated the anti-tumor effects of reversine on cell viability, colony formation, apoptosis, and cell cycle in 786-O and ACHN cell lines.
Results: It was demonstrated that reversine significantly inhibited the proliferation of both cell lines in time- and dose-dependent manners. Polyploidy formation was observed under high-concentration reversine treatment. In addition, reversine induced cell death via caspase-dependent apoptotic pathways, which could be partially inhibited by Z-VAD-FMK, a pan-caspase inhibitor.
Conclusion: Reversine could effectively suppress the proliferation of human RCC cells, and may serve as a novel therapeutic regimen for RCC in clinical practice.
Keywords: anti-cancer, apoptosis, Aurora kinase, human renal cell carcinoma, polyploidy, reversine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]